On Cancer

Filter by Tag

Profile

By Jim Stallard, MA, Writer/Editor | Friday, April 26, 2013

Physician-scientist Liang Deng cares for patients with melanoma and other skin cancers, and also conducts innovative research on poxviruses.

Tags: Cancer Biology; Immunology; Treatment; Melanoma; Research

In the Clinic

Combining Two FDA-Approved Drugs May Be Harmful for Patients with Metastatic Melanoma

By Media Staff | Thursday, April 4, 2013

Early research led by investigators at Memorial Sloan-Kettering cautions against combining ipilimumab and vemurafenib for the treatment of metastatic melanoma.

Tags: Cancer Care; Clinical Trials; Immunotherapy; Treatment; Melanoma; Research

Finding

New England Journal of Medicine Case Study Reveals New Information about Advanced Melanoma Treatment

By Memorial Sloan-Kettering | Friday, December 7, 2012

Memorial Sloan-Kettering experts add to their knowledge of vemurafenib, a drug recently approved by the FDA to treat some patients with metastatic melanoma.

Tags: Cancer Care; Treatment; Melanoma; Research

Q&A

At Work: Physician-Scientist Ping Chi

By Julie Grisham, MS, Science Writer/Editor | Friday, November 2, 2012

Dr. Chi, a physician-scientist and member of the Human Oncology and Pathogenesis Program, studies genetic and epigenetic changes that cause cancer.

Tags: Cancer Care; Cancer Genetics; Targeted Therapy; Melanoma; Soft Tissue Sarcoma; Research

Patient Story

James's Story about Melanoma

By Andrea Peirce, BA, Writer/Editor | Monday, October 15, 2012

James had advanced melanoma and dwindling treatment options when his doctors enrolled him in a clinical trial of an innovative immunotherapy developed at Memorial Sloan-Kettering.

Tags: Cancer Care; Melanoma; Survivorship

Feature

Cancer Genomics: Improved Understanding of Molecular Changes in Tumors Produces More-Specialized Treatments

By Jim Stallard, MA and Julie Grisham, MS
Friday, September 21, 2012

With the genomics revolution, scientists and physicians have increasingly been able to peer at the inner workings of tumor cells and pinpoint the specific genetic changes that transform them from their cells of origin into cancer.

Tags: Cancer Genetics; Acute Myelogenous Leukemia; Colorectal Cancer; Leukemias; Lung Cancer; Melanoma; Pancreatic Cancer; Soft Tissue Sarcoma; Stomach (Gastric) Cancer; Research

In the Clinic

Rare Medical Phenomenon: Melanoma Patient’s Tumors Disappear throughout the Body after Radiation of One Tumor

By Media Staff | Thursday, March 8, 2012

Findings from a multidisciplinary research team led by Memorial Sloan-Kettering medical oncologist and immunologist Jedd Wolchok could help shed light on the immune system’s role in fighting cancer.

Tags: Immunotherapy; Radiation Therapy; Immunology; Melanoma; Research

In the News

Memorial Sloan-Kettering Made Major Contributions to Cancer Advances in 2011

By Julie Grisham, MS, Science Writer/Editor | Monday, February 6, 2012

Two of the year’s top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan-Kettering investigators.

Tags: Cancer Care; Personalized Medicine; Targeted Therapy; Melanoma; Ovarian Cancer; Prostate Cancer; Research

Finding

Study Finds Most Children Don't Use Sunscreen Regularly

By Esther Napolitano, BS, Science Writer/Editor | Monday, January 23, 2012

Research has shown that children who have experienced a sunburn at an early age are at almost double the risk for developing melanoma in adulthood. Now, a new study led by Memorial Sloan-Kettering epidemiologist Stephen Dusza finds that most children do not regularly use sunscreen.

Tags: Cancer Care; Melanoma

Honor

Memorial Sloan-Kettering Researchers Appointed to Stand Up To Cancer Melanoma “Dream Team”

By Media Staff | Wednesday, December 14, 2011

Five Memorial Sloan-Kettering scientists have been appointed to a new research team dedicated to identifying targets for therapies to treat a certain form of melanoma.

Tags: Melanoma; Research

In the Lab

Researchers Discover Why New Melanoma Drug Stops Working

By Media Staff | Wednesday, November 23, 2011

Research led by investigators at Memorial Sloan-Kettering has identified a previously unknown mechanism of resistance to the newly approved melanoma drug vemurafenib.

Tags: Drug Discovery; Targeted Therapy; Melanoma; Research